Missed rifampicin and isoniazid resistance by commercial molecular assays
Drug-resistant tuberculosis (TB) has poor outcomes unless resistance is detected early, ideally by commercially available molecular tests. We present a case of occult multidrug-resistant TB where both rifampicin and isoniazid resistance were missed by molecular testing and were only identified...
Saved in:
Main Authors: | L Richards, F Ismail, J Nel, S V Omar |
---|---|
Format: | Article |
Language: | English |
Published: |
South African Medical Association
2024-07-01
|
Series: | South African Medical Journal |
Subjects: | |
Online Access: | https://samajournals.co.za/index.php/samj/article/view/1779 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020
by: M.L. Rekart, et al.
Published: (2024-07-01) -
Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital
by: Gina Gualano, et al.
Published: (2024-12-01) -
TB drug susceptibility testing in high fluoroquinolone resistance settings
by: F. Saluzzo, et al.
Published: (2024-05-01) -
Three months of weekly rifapentine plus isoniazid for TB prevention among people with HIV
by: R. Borse, et al.
Published: (2024-09-01) -
Assessment of Rifampicin Resistance in Presumptive Tuberculosis Cases at Dadeldhura Hospital of Sudurpaschim Province of Nepal
by: Madan Singh Bohara
Published: (2025-02-01)